Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Drug distribution is influenced by which of the following factors?

All of these. **Explanation:** Drug distribution is the reversible transfer of a drug from the systemic circulation to the various organs and tissues of the body. This process is governed by several physicochemical and physiological factors: 1. **Plasma Protein Binding:** Drugs bound to plasma proteins (like albumin for acidic drugs and $\alpha_1$-acid glycoprotein for basic drugs) are trapped in the vascular compartment because the protein-drug complex is too large to cross capillary membranes. Only the **free (unbound) fraction** can distribute into tissues. 2. **Lipid Solubility:** The cell membrane is a lipid bilayer. Highly lipid-soluble (lipophilic) drugs cross biological membranes easily and distribute extensively into tissues, often resulting in a high **Volume of Distribution ($V_d$)**. 3. **Blood Flow (Perfusion):** Distribution occurs more rapidly in highly perfused organs (brain, heart, liver, kidneys) compared to poorly perfused tissues (skeletal muscle, fat, bone). **Why "All of these" is correct:** Since distribution depends on the drug's ability to leave the blood (binding), cross membranes (solubility), and reach the site (blood flow), all three factors are critical determinants. **Clinical Pearls for NEET-PG:** * **Volume of Distribution ($V_d$):** A theoretical volume; drugs with high $V_d$ (e.g., Digoxin, Chloroquine) are sequestered in tissues and cannot be removed by hemodialysis. * **Redistribution:** Highly lipid-soluble drugs (e.g., **Thiopentone**) initially enter the brain but quickly redistribute to less perfused tissues like fat, leading to a short duration of action despite a long half-life. * **Blood-Brain Barrier (BBB):** Only highly lipid-soluble, non-ionized drugs can cross the BBB.

Q: What is implied if a drug has more renal clearance than the Glomerular Filtration Rate (GFR)?

The drug is secreted in the renal tubules.. ### Explanation The net renal excretion of a drug is the result of three processes: **Glomerular Filtration + Tubular Secretion - Tubular Reabsorption.** **1. Why Option B is Correct:** The Glomerular Filtration Rate (GFR) represents the volume of plasma filtered through the glomeruli per unit of time (normal $\approx$ 125 mL/min). If a drug's renal clearance is **greater than the GFR**, it means that more drug is appearing in the urine than can be accounted for by filtration alone. This additional amount must be added to the tubular fluid via **active tubular secretion** (occurring primarily in the proximal convoluted tubule). **2. Why Other Options are Incorrect:** * **Option A:** If a drug is **reabsorbed**, its renal clearance will be **less than the GFR** (e.g., Glucose has zero clearance because it is 100% reabsorbed). * **Option C:** Biliary excretion refers to drug elimination via feces and does not contribute to the calculation of *renal* clearance. * **Option D:** If a drug is neither secreted nor reabsorbed, its renal clearance will be **equal to the GFR** (e.g., Inulin or Creatinine). ### High-Yield Clinical Pearls for NEET-PG * **Inulin Clearance:** The gold standard for measuring GFR because it is freely filtered but neither secreted nor reabsorbed ($Cl_{renal} = GFR$). * **Para-amino hippuric acid (PAH):** Used to measure **Renal Plasma Flow** because it is both filtered and extensively secreted ($Cl_{renal} > GFR$). * **Competition for Secretion:** Drugs using the same secretory transporters can compete, leading to interactions. *Example:* **Probenecid** inhibits the tubular secretion of **Penicillin**, thereby increasing its half-life and plasma concentration. * **Protein Binding:** Only the unbound (free) fraction of a drug is filtered, but tubular secretion can clear both free and protein-bound drugs.

Q: What is the clearance of a drug?

The volume of plasma cleared of the drug per unit of time.. **Explanation:** **1. Why Option A is Correct:** Clearance ($CL$) is a fundamental pharmacokinetic parameter defined as the **volume of plasma** from which a drug is completely removed per unit of time (e.g., mL/min or L/hr). It represents the efficiency of drug elimination. The key conceptual takeaway is that clearance refers to the **volume of fluid processed**, not the absolute amount of the drug removed. It is mathematically expressed as: $$CL = \frac{\text{Rate of elimination}}{\text{Plasma concentration (C)}}$$ **2. Why Other Options are Incorrect:** * **Option B:** This describes **renal excretion**, which is only one component of total body clearance. Clearance also includes hepatic metabolism and biliary excretion. Furthermore, "amount" refers to mass (mg), whereas clearance is a volume-based rate. * **Option C:** This describes the **Rate of Elimination**. While clearance and rate of elimination are related, they are not identical. In first-order kinetics, the rate of elimination changes as the drug concentration falls, but the **clearance remains constant**. **3. NEET-PG High-Yield Clinical Pearls:** * **Total Body Clearance ($CL_{total}$):** Sum of $CL_{renal} + CL_{hepatic} + CL_{other}$. * **First-order vs. Zero-order:** For most drugs (first-order), clearance is constant. For drugs like Phenytoin, Ethanol, and Aspirin (zero-order/saturation kinetics), clearance decreases as the plasma concentration increases. * **Maintenance Dose (MD):** Clearance is the primary determinant for calculating the MD. * $MD = \text{Target } C_{ss} \times CL$ * **Half-life ($t_{1/2}$):** Clearance is inversely proportional to half-life ($t_{1/2} = 0.693 \times V_d / CL$). If clearance decreases (e.g., renal failure), the half-life increases.

Q: Which of the following is NOT true for the sublingual route of drug administration?

All drugs can be administered via this route.. ### Explanation The sublingual route involves placing a drug under the tongue, where it dissolves and is absorbed through the rich capillary network of the oral mucosa directly into the systemic circulation. **Why Option B is the Correct Answer (The False Statement):** Not all drugs can be administered sublingually. To be effective via this route, a drug must be **lipid-soluble, non-irritating, and potent** (effective in small doses). Large, water-soluble molecules or drugs with an unpleasant taste are unsuitable. Furthermore, if a drug requires a very high dose, the limited surface area of the sublingual mucosa cannot accommodate it. **Analysis of Other Options:** * **Option A (Bypasses first-pass metabolism):** This is **true**. Venous drainage from the mouth goes directly into the superior vena cava, bypassing the portal circulation and the liver. This increases the bioavailability of drugs like Nitroglycerin. * **Option C (Termination of action):** This is **true**. If side effects occur or the desired effect is reached, the patient can simply spit out the remaining tablet, stopping further absorption. * **Option D (Rapid absorption):** This is **true**. Due to the high vascularity of the sublingual mucosa, drugs reach the bloodstream quickly, making this route ideal for emergencies (e.g., angina). **NEET-PG High-Yield Pearls:** * **Classic Example:** **Nitroglycerin (GTN)** is the prototype for sublingual administration in acute angina. * **Other Drugs:** Buprenorphine, Desmopressin, and Nifedipine (though oral/bite-and-swallow is now preferred for Nifedipine due to safety). * **Key Advantage:** Avoids destruction by gastric acid and digestive enzymes (e.g., why certain peptides are explored for this route). * **Key Disadvantage:** It can cause irritation of the oral mucosa and is inconvenient for frequent dosing.

Q: What is the active metabolite of carisoprodol?

Meprobamate. **Explanation:** **Carisoprodol** is a centrally acting skeletal muscle relaxant used for the relief of acute, painful musculoskeletal conditions. Its primary mechanism of action is mediated through its conversion into its active metabolite, **Meprobamate**. 1. **Why Meprobamate is correct:** Carisoprodol is a prodrug. Once ingested, it undergoes extensive hepatic metabolism via the cytochrome P450 enzyme **CYP2C19** to form Meprobamate. Meprobamate itself is an anxiolytic and sedative-hypnotic drug (historically used as a tranquilizer) that acts as a positive allosteric modulator at the **GABA-A receptor**. This metabolite accounts for much of the therapeutic muscle relaxant effect, as well as the drug's potential for abuse and sedation. 2. **Analysis of Incorrect Options:** * **Amphetamine:** This is a CNS stimulant. It is not a metabolite of carisoprodol; however, it is a metabolite of the anti-parkinsonian drug *Selegiline*. * **Doxylamine:** This is a first-generation antihistamine (H1 antagonist) with sedative properties, commonly used as a sleep aid. * **Dimethadione:** This is the active metabolite of the anticonvulsant *Trimethadione*. **NEET-PG High-Yield Pearls:** * **Abuse Potential:** Due to the Meprobamate metabolite, carisoprodol is classified as a Schedule IV controlled substance. It can cause withdrawal symptoms similar to benzodiazepines. * **Pharmacogenomics:** Patients who are "poor metabolizers" of **CYP2C19** will have higher serum levels of carisoprodol and lower levels of meprobamate, altering the drug's efficacy and toxicity profile. * **Other Muscle Relaxants to Remember:** * *Baclofen:* GABA-B agonist. * *Tizanidine:* Alpha-2 agonist. * *Dantrolene:* Acts directly on the Ryanodine receptor (RyR1) in the sarcoplasmic reticulum.

Q: Therapeutic index is a measure of?

Safety. **Explanation:** **Therapeutic Index (TI)** is a quantitative measurement of the relative **safety** of a drug. It represents the ratio between the dose that produces toxicity and the dose that produces the desired therapeutic effect. Mathematically, it is expressed as: **TI = TD₅₀ / ED₅₀** (or LD₅₀ / ED₅₀ in animal studies) * **TD₅₀:** Dose that produces a toxic effect in 50% of the population. * **ED₅₀:** Dose that produces a therapeutic effect in 50% of the population. A **higher TI** indicates a wider margin of safety, meaning there is a large gap between the effective dose and the toxic dose (e.g., Penicillin, Paracetamol). Conversely, a **narrow TI** means the therapeutic and toxic doses are close, requiring frequent plasma drug monitoring (e.g., Lithium, Digoxin, Warfarin). **Why other options are incorrect:** * **Efficacy (A):** Refers to the maximum response ($E_{max}$) a drug can produce, regardless of dose. It is a measure of a drug's effectiveness, not safety. * **Adverse effects (B):** While TI relates to toxicity, it is a ratio comparing benefit to risk, not a measure of the side effects themselves. * **Potency (D):** Refers to the amount of drug (dose) required to produce an effect of a given intensity ($EC_{50}$). A more potent drug requires a smaller dose but is not necessarily safer. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs with Narrow Therapeutic Index (Mnemonic: Warning! Death Is Likely):** **W**arfarin, **D**igoxin, **I**nsulin, **L**ithium, **L**evothyroxine, **P**henytoin, **T**heophylline. * **Therapeutic Window:** The range of drug dosages which can treat disease effectively without having toxic effects. * **Certain Safety Factor:** Calculated as $LD_1 / ED_{99}$; it is a more stringent measure of safety than TI.

Q: Which of the nitrates can undergo first-pass metabolism?

All of the above. **Explanation:** The correct answer is **D. All of the above.** The underlying pharmacological concept here is **High First-Pass Metabolism (FPM)**. Organic nitrates are highly lipid-soluble drugs that are rapidly and extensively metabolized by the enzyme **glutathione-organic nitrate reductase** in the liver before reaching the systemic circulation. * **Nitroglycerine (Glyceryl Trinitrate - GTN):** It has a very high FPM (bioavailability <10%). This is why it is traditionally administered via the sublingual route to bypass the liver and provide rapid relief in angina. * **Isosorbide dinitrate (ISDN):** This also undergoes significant hepatic metabolism. While it can be given orally, its oral bioavailability is low (approx. 20-25%), and it is converted into active metabolites like Isosorbide-5-mononitrate. * **Pentaerythritol tetranitrate (PETN):** Like other organic nitrates, it is susceptible to hepatic degradation, necessitating higher oral doses to achieve therapeutic levels. **Why other options are "incorrect" as standalone choices:** Options A, B, and C are all individual nitrates that undergo first-pass metabolism. Since all three share this pharmacokinetic property, "All of the above" is the most accurate clinical answer. **High-Yield Clinical Pearls for NEET-PG:** 1. **Isosorbide-5-mononitrate:** Unlike the drugs listed above, this is the only nitrate that **does not** undergo significant first-pass metabolism (100% bioavailability). It is the preferred oral nitrate for chronic prophylaxis. 2. **Tachyphylaxis:** Continuous use of nitrates leads to "nitrate tolerance" due to the depletion of free sulfhydryl (-SH) groups. A "nitrate-free interval" of 8–12 hours is required daily to restore sensitivity. 3. **Monday Disease:** Workers in explosive factories (exposed to GTN) develop tolerance during the week but lose it over the weekend, leading to severe headaches (vasodilation) upon returning to work on Mondays.

Question 1

Drug distribution is influenced by which of the following factors?

Accepted Answer

All of these

Answer

Plasma protein binding

Answer

Lipid solubility

Answer

Degree of blood flow

Question 2

What is implied if a drug has more renal clearance than the Glomerular Filtration Rate (GFR)?

Accepted Answer

The drug is secreted in the renal tubules.

Answer

The drug is reabsorbed in the renal tubules.

Answer

The drug is excreted in bile.

Answer

The drug is neither secreted nor reabsorbed.

Question 3

What is the clearance of a drug?

Accepted Answer

The volume of plasma cleared of the drug per unit of time.

Answer

The amount of drug excreted in the urine.

Answer

The amount of drug metabolized per unit of time.

Answer

All of the above.

Question 4

Which of the following is NOT true for the sublingual route of drug administration?

Accepted Answer

All drugs can be administered via this route.

Answer

It allows drugs to bypass first-pass metabolism.

Answer

The action of the drug can be terminated at any time.

Answer

It provides rapid absorption of the drug.

Question 5

Which of the following compounds does not cross the blood-brain barrier?

Accepted Answer

Pralidoxime

Answer

Obidoxime

Answer

Diacetyl monoxime

Answer

Physostigmine

Question 6

Which of the following factors is affected by the bioavailability of a drug?

Accepted Answer

Dose of the drug

Answer

Half-life of the drug

Answer

Volume of distribution

Answer

pKa value

Question 7

What is the active metabolite of carisoprodol?

Accepted Answer

Meprobamate

Answer

Amphetamine

Answer

Doxylamine

Answer

Dimethadione

Question 8

What is the most important mechanism of drug transport across the cell membrane?

Accepted Answer

Passive diffusion

Answer

Filtration

Answer

Active transport

Answer

Facilitated diffusion

Question 9

Therapeutic index is a measure of?

Accepted Answer

Safety

Answer

Efficacy

Answer

Adverse effects

Answer

Potency

Question 10

Which of the nitrates can undergo first-pass metabolism?

Accepted Answer

All of the above

Answer

Nitroglycerine

Answer

Pentaerythritol tetranitrate

Answer

Isosorbide dinitrate

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?